RecruitingPhase 3NCT07362017

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

A Multicenter, Open Label Study to Investigate the Safety and Efficacy of Ponesimod in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis

Sponsor

Vanda Pharmaceuticals

Enrollment

300 participants

Start Date

Feb 17, 2026

Study Type

INTERVENTIONAL

Conditions

Moderate-to-severe Chronic Plaque Psoriasis

Summary

An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ponesimod for people with moderate-to-severe chronic plaque psoriasis. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPonesimod

Oral Tablet

Locations(4)

Vanda Investigational Site

Glendale, Arizona, United States

Vanda Investigational Site

Fremont, California, United States

Vanda Investigational Site

Rochester, New York, United States

Vanda Investigational Site

Spokane, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07362017